NDA 016084 · Casper Pharma LLC
Zyloprim
Allopurinol · Oral · Xanthine Oxidase Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1966
Aug 19, 1966
Approved uses
1
Original approval plus efficacy supplements
Registered trials
209
51 Phase 3, 13 recruiting
FAERS reports
157,733
129,250 serious, 22,110 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 21, 2026.
Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol tablet is not recommended for the treatment of asymptomatic hyperuricemia. Allopurinol tablet is a xanthine oxidase inhibitor indicated for the management of: Adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) ( 1 ) Adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels ( 1 ) Adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes ( 1 ) Limitations of Use Allopurinol tablet is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 )
Mechanism: Allopurinol is a structural analogue of the natural purine base, hypoxanthine. Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 1966 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- ZYLOPRIM · ALLOPURINOL 200MG · TABLET, ORAL · Prescription · TE AB
- ZYLOPRIM · ALLOPURINOL 100MG · TABLET, ORAL · Prescription · TE AB
- ZYLOPRIM · ALLOPURINOL 300MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Allopurinol" as an intervention, any sponsor and status, largest first.
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01101035 · 6,198 participants · Start Apr 23, 2010 · Primary completion May 15, 2017
Drug: Febuxostat; Allopurinol · For: Cardiovascular Disease
Sites: Decatur, Georgia; Dunwoody, Georgia; Marietta, Georgia · 203 sites in all
- Efficacy and Safety of Oral Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00430248 · 2,269 participants · Start Feb 2007 · Primary completion Mar 2008
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
Sites: Birmingham, Alabama; Hoover, Alabama; Hueytown, Alabama · 258 sites in all
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsPivotal-lookingCompleted
LG ChemIndustry
NCT05586971 · 2,202 participants · Start Mar 30, 2023 · Primary completion May 6, 2025
Drug: Tigulixostat; Allopurinol and 1 more · For: Gout; Hyperuricemia; Gout Flare and 1 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 279 sites in all
- Allopurinol Outcome StudyCompleted
Ardea Biosciences, Inc.Industry
NCT01391325 · 1,735 participants · Start Jul 2011 · Primary completion Jan 2013
Drug: Allopurinol · For: Gout
Sites: Birmingham, Alabama; Bringham, Alabama; Calera, Alabama · 173 sites in all
- Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT00856206 · 1,315 participants · Start Mar 2009 · Primary completion Jan 2011
Drug: Rilonacept · For: Gout
Sites: Alabaster, Alabama; Mesa, Arizona; Burbank, California · 124 sites in all
- The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular RiskPivotal-lookingRecruiting
Poznan University of Medical SciencesAcademic, hospital or other
NCT05943821 · 1,116 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 31, 2028
Drug: Allopurinol 200 mg; Optional intervention · For: Cardiovascular Diseases; Uric Acid
Sites: Poznan, Poland
- Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00175019 · 1,086 participants · Start Jul 2003 · Primary completion Feb 2007
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
- Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00174915 · 1,072 participants · Start Feb 2003 · Primary completion Apr 2004
Drug: Febuxostat; Febuxostat and 3 more · For: Gout
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea8,831
- fatigue8,385
- dyspnoea8,016
- nausea7,396
- death6,985
- acute kidney injury6,871
- off label use6,805
- pyrexia6,125
- pneumonia5,754
- asthenia5,712
- anaemia5,511
- drug ineffective5,239
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,482 |
| 2005 | 2,097 |
| 2006 | 2,078 |
| 2007 | 1,811 |
| 2008 | 2,226 |
| 2009 | 2,744 |
| 2010 | 3,358 |
| 2011 | 4,397 |
| 2012 | 5,349 |
| 2013 | 5,158 |
| 2014 | 5,525 |
| 2015 | 8,242 |
| 2016 | 9,189 |
| 2017 | 9,475 |
| 2018 | 12,939 |
| 2019 | 13,166 |
| 2020 | 12,834 |
| 2021 | 11,186 |
| 2022 | 10,728 |
| 2023 | 9,249 |
| 2024 | 8,953 |
| 2025 | 9,066 |
| 2026 | 6,469 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, et al. · N Engl J Med 2018 · Comparative Study, Equivalence Trial
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR, Wortmann RL, et al. · N Engl J Med 2005 · Clinical Trial, Phase III, Comparative Study
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Dalbeth N, Billington K, Doyle A, et al. · Arthritis Rheumatol 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV, Pascoe EM, Tiku A, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Febuxostat for treating chronic gout.
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Casper Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.